NAS:BGNE (Cayman Islands) Also trade in: Germany Hongkong

BeiGene Ltd

$ 124.36 -0.04 (-0.03%)
Volume: 160,584 Avg Vol (1m): 270,456
Market Cap $: 7.43 Bil Enterprise Value $: 5.95 Bil
P/E (TTM): 0.00 P/B: 4.57
Earnings Power Value -131.72
Net Current Asset Value 21.1
Tangible Book 27.42
Projected FCF 0
Median P/S Value 153.96
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 6.4/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt 6.68
Cash-To-Debt range over the past 10 years
Min: 0.14, Med: 7.55, Max: 39.79
Current: 6.68
0.14
39.79
Equity-to-Asset 0.74
Equity-to-Asset range over the past 10 years
Min: 0.48, Med: 0.74, Max: 0.92
Current: 0.74
0.48
0.92
Debt-to-Equity 0.15
Debt-to-Equity range over the past 10 years
Min: -0.71, Med: 0.13, Max: 0.6
Current: 0.15
-0.71
0.6
Debt-to-EBITDA -0.32
Debt-to-EBITDA range over the past 10 years
Min: -8.7, Med: -0.68, Max: -0.15
Current: -0.32
-8.7
-0.15
Piotroski F-Score 2
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 7.29
DISTRESS
GREY
SAFE
Beneish M-Score -0.76
Not Manipulator
Manipulator

Profitability & Growth : 5/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % -315.55
Operating Margin range over the past 10 years
Min: -10940.19, Med: -238.47, Max: -41.3
Current: -315.55
-10940.19
-41.3
Net Margin % -302.45
Net Margin range over the past 10 years
Min: -11141.78, Med: -240.07, Max: -39.06
Current: -302.45
-11141.78
-39.06
ROE % -46.76
ROE range over the past 10 years
Min: -114.09, Med: -55.89, Max: -18.25
Current: -46.76
-114.09
-18.25
ROA % -36.13
ROA range over the past 10 years
Min: -67.02, Med: -50.76, Max: -12.85
Current: -36.13
-67.02
-12.85
ROC (Joel Greenblatt) % -537.20
ROC (Joel Greenblatt) range over the past 10 years
Min: -904.62, Med: -376.08, Max: -67.2
Current: -537.2
-904.62
-67.2
3-Year Total Revenue Growth Rate 183.10
3-Year Revenue Growth Rate range over the past 10 years
Min: -45, Med: 134.4, Max: 185.1
Current: 134.4
-45
185.1
3-Year Total EBITDA Growth Rate -133.40
3-Year EBITDA Growth Rate range over the past 10 years
Min: -294.7, Med: -103.1, Max: -93.3
Current: -93.3
-294.7
-93.3

» BGNE's 30-Y Financials

Financials (Next Earnings Date: 2019-08-09)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:BGNE

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Biotechnology » Biotechnology    NAICS : 325412    SIC : 2834
Compare NAS:SAGE NAS:NBIX NAS:EXEL NAS:SGEN XKRX:215600 NAS:IONS TSE:4587 NAS:TECH HKSE:01530 HKSE:01548 NAS:ALKS BOM:532523 XKRX:128940 NAS:SRPT NAS:JAZZ NAS:BLUE SZSE:000661 NAS:AGIO OSTO:SOBI NAS:UTHR
Traded in other countries 49BA.Germany 06160.Hongkong
Address c/o Mourant Governance Services (Cayman) Limited, 94 Solaris Avenue, Camana Bay, Grand Cayman, CYM, KY1-1108
BeiGene Ltd is a United States based clinical-stage biopharmaceutical company. It is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The company has developed a proprietary cancer biology platform that addresses the importance of tumor-immune system interactions and the value of primary biopsies in developing new models to support its drug discovery effort. It has developed clinical-stage drug candidates that inhibit the important oncology targets Bruton's tyrosine kinase, or BTK; RAF dimer protein complex and PARP family of proteins, and an immuno-oncology agent that inhibits the immune checkpoint protein receptor PD-1.

Ratios

Current vs industry vs history
PB Ratio 4.57
PB Ratio range over the past 10 years
Min: 3.19, Med: 4.62, Max: 5.35
Current: 4.57
3.19
5.35
PS Ratio 28.82
PS Ratio range over the past 10 years
Min: 27.52, Med: 35.74, Max: 58.56
Current: 28.82
27.52
58.56
EV-to-EBIT -7.67
EV-to-EBIT range over the past 10 years
Min: -15.2, Med: -8.9, Max: -7.26
Current: -7.67
-15.2
-7.26
EV-to-EBITDA -7.81
EV-to-EBITDA range over the past 10 years
Min: -15.5, Med: -9, Max: -7.4
Current: -7.81
-15.5
-7.4
EV-to-Revenue 24.45
EV-to-Revenue range over the past 10 years
Min: 23.6, Med: 30, Max: 51.1
Current: 24.45
23.6
51.1
Current Ratio 7.52
Current Ratio range over the past 10 years
Min: 0.14, Med: 7.71, Max: 15.91
Current: 7.52
0.14
15.91
Quick Ratio 7.47
Quick Ratio range over the past 10 years
Min: 0.14, Med: 7.65, Max: 15.91
Current: 7.47
0.14
15.91
Days Inventory 5.83
Days Inventory range over the past 10 years
Min: 5.83, Med: 7.14, Max: 7.28
Current: 5.83
5.83
7.28
Days Sales Outstanding 88.52
Days Sales Outstanding range over the past 10 years
Min: 45.06, Med: 60.33, Max: 88.52
Current: 88.52
45.06
88.52
Days Payable 48.92
Days Payable range over the past 10 years
Min: 44.52, Med: 56.1, Max: 92.96
Current: 48.92
44.52
92.96

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -20.70
3-Year Share Buyback Rate range over the past 10 years
Min: -20.7, Med: 4.7, Max: 9
Current: -20.7
-20.7
9

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 4.54
Price-to-Tangible-Book range over the past 10 years
Min: 4.33, Med: 4.8, Max: 5.24
Current: 4.54
4.33
5.24
Price-to-Median-PS-Value 0.81
Price-to-Median-PS-Value range over the past 10 years
Min: 0.77, Med: 1.09, Max: 1.62
Current: 0.81
0.77
1.62
Earnings Yield (Joel Greenblatt) % -12.88
Earnings Yield (Greenblatt) range over the past 10 years
Min: -13.64, Med: -11.2, Max: -6.6
Current: -12.88
-13.64
-6.6

More Statistics

Revenue (TTM) (Mil) $ 243.51
EPS (TTM) $ -12.74
Beta 1.19
Volatility % 47.25
52-Week Range $ 105.19 - 194.56
Shares Outstanding (Mil) 59.9

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 2
Positive ROA N
Positive CFROA N
Higher ROA yoy N
CFROA > ROA Y
Lower Leverage yoy Y
Higher Current Ratio yoy N
Less Shares Outstanding yoy N
Higher Gross Margin yoy N
Higher Asset Turnover yoy N